Description

Semaglutide (rDNA origin) is a long-acting GLP-1 receptor agonist produced using recombinant DNA technology. It is designed to provide sustained glycemic control and support weight reduction by targeting key metabolic pathways.

Mechanism of Action:
Semaglutide mimics the natural GLP-1 hormone to:

• Stimulate glucose-dependent insulin secretion
• Suppress glucagon release
• Delay gastric emptying
• Reduce appetite and caloric intake

Key Features:

• Long-acting formulation for improved patient compliance
• 5 mg strength for precise dose titration
• High purity & consistency via rDNA manufacturing
• Supports both glycemic control and weight management